For research use only
| Cat No. | ABC-TC0084 |
| Product Type | Human Breast Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Product Code | BT20/nKR, BT-20 nKR, BT20 nKR, BT-20/nkr |
BT-20/nKR is a breast cancer cell line resistant to NK cells, ideal for tumor immunology, drug screening, and studies of immune escape mechanisms.
BT-20/nKR cell line is a human triple-negative breast adenocarcinoma cell line, originally derived in 1958 from an invasive ductal carcinoma of a 74-year-old Caucasian female. Exhibiting typical epithelial-like morphology, these cells grow as adherent monolayers and display a hyperdiploid karyotype with chromosome amplifications at regions including 6, 11, and 20. A typical feature of BT-20/nKR is an estrogen receptor alpha (ERα) splice variant lacking exon 5, consistent with an estrogen receptor-negative phenotype. BT-20/nKR also harbors mutations in TP53 and PIK3CA, both of which are common drivers in breast cancer pathology. The cells undergo stringent screening and testing procedures to ensure they are free from contamination by Mycoplasma, fungi, yeast, and bacteria.
| Product Code | BT20/nKR, BT-20 nKR, BT20 nKR, BT-20/nkr |
| Species | Human |
| Cat.No | ABC-TC0084 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
| Stock | Out of stock |
BT-20/nKR cells provide a valuable in vitro model for investigating triple-negative breast cancer (TNBC), particularly the basal-like subtype, drug responsiveness, and mechanotransduction pathways. Their defined mutations in TP53 and PIK3CA, along with a unique ERα splice variant, support studies of oncogenic signaling, transcriptional regulation, and therapy resistance. Moreover, recent nanomechanical studies have demonstrated distinct viscoelastic properties compared to other breast cancer lines, enabling their use in exploring cytoskeletal remodeling and biomechanical profiling using atomic force microscopy (AFM) and nanomotion assays.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
